The scientific director of the Genyo center, Marta Alarcón Riquelme, coordinates the 3TR project, which aims to improve the response to treatment in autoimmune, inflammatory and allergic diseases.

The GENyO center has become the European epicenter of lupus research in recent years with the scientific leadership by Marta Alarcón Riquelme of the European 3TR project, the largest Immunology initiative of the Innovative Medicines Initiative 2 (IMI2), to improve the management of patients who do not respond to therapy in seven diseases mediated by the immune system, including lupus.

This action, which began its journey in 2019, is endowed with 80 million euros and has the active participation of nine international pharmaceutical companies. Samples from more than 1,000 lupus patients are currently being analyzed by multi-omics methods. While awaiting the results, lupus patients, who already number 153 in Andalusia, continue to be recruited to participate in this study.

Read the complete article: https://acortar.link/Xl19c7

See more news